Ignite Creation Date:
2024-05-05 @ 12:09 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00250029
Status:
COMPLETED
Last Update Posted:
2011-09-27
First Post:
2005-11-03
Brief Title:
Gene Expression Analysis of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin Based Chemotherapy Regimen
Sponsor:
New Mexico Cancer Care Alliance
Organization:
New Mexico Cancer Care Alliance
Study Overview
Official Title:
Gene Expression Analysis of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin Based Chemotherapy
Status:
COMPLETED
Status Verified Date:
2010-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
11 To collect pathological tumor specimens of patients with metastatic colorectal cancer in a prospective fashion for correlative studies of response to an oxaliplatin based chemotherapy regimen
12 To determine a gene expression profile that predicts response to an oxaliplatin based chemotherapy regimen in this cohort of patients
12 To determine a gene expression profile that predicts response to an oxaliplatin based chemotherapy regimen in this cohort of patients
Detailed Description:
This is a single-arm non-randomized trial of oxaliplatin and capecitabine Patients that are placed on other studies that utilize the same chemotherapy regimen can enter this study Those patients will be treated according to the clinical study on which they have been entered For patients not on another clinical trial the treatment outlined below should be followed
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None